Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DHA,Arachidonic Acid
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study on the Effect of DHA & ARA Candy on the Cognitive Improvement in Preschool Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : DHA,Arachidonic Acid
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Unity Health Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Response Investigation of Docosahexaenoic Acid (DHA)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2024
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Unity Health Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mixture Of Extracts,DHA
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Consuming a Mixture of Extracts and DHA on the Mild Cognitive Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : Mixture Of Extracts,DHA
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Mead Johnson Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Mead Johnson Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...
Product Name : Altemia
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Pentec Health
Deal Size : Undisclosed
Deal Type : Agreement
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Infant Formula Update: June 17, 2022
Details : Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.
Product Name : Aptamil
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 17, 2022
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DHA,Icosapent Ethyl
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Hofseth BioCare
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo (docosahexaenoic acid), HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.
Product Name : OmeGo
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : DHA,Icosapent Ethyl
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Hofseth BioCare
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Icosapent Ethyl,DHA
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Icosapent Ethyl,DHA
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl,DHA
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Aker BioMarine
Deal Size : Undisclosed
Deal Type : Collaboration
Aker BioMarine Enters Into Research Collaboration for Alzheimer’s
Details : Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.
Product Name : Lysoveta
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 15, 2021
Lead Product(s) : Icosapent Ethyl,DHA
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Aker BioMarine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 21, 2020
Lead Product(s) : DHA,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable